Sacituzumab Govitecan Drug Aliquot | Anti-Trop-2 | Therapeutic ADC

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Sacituzumab Govitecan are now available as research consumables.

Sacituzumab Govitecan drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Sacituzumab Govitecan Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Trodelvy® / Sacituzumab Govitecan Reference Product

Drug nameTrodelvy®
INNSacituzumab Govitecan
API typeSacituzumab Govitecan is a Trop-2-directed antibody-drug conjugate (ADC). Sacituzumab is a humanised monoclonal antibody (hRS7 IgG1κ) that recognises Trop-2. The small molecule, SN-38, is a topoisomerase I inhibitor, which is covalently attached to the antibody by a hydrolysable linker. Approximately 7-8 molecules of SN-38 are attached to each antibody molecule.
Pharmacotherapeutic group
Immunosuppressants, selective immunosuppressants.
ATC code
L01FX17
Target of antibody
Trop-2
General functionSacituzumab Govitecan as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Sacituzumab Govitecan binds to Trop-2-expressing cancer cells and is internalised with the subsequent release of SN-38 from a hydrolysable linker. SN-38 interacts with topoisomerase I and prevents re-ligation of topoisomerase I-induced single strand breaks. The resulting DNA damage leads to apoptosis and cell death.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Information not available.
Original license holder
Gilead Sciences Ireland UC
Marketing authorisation numbers
EU/1/21/1592/001
Marketing authorisation holder
Gilead Sciences Ireland UC
Carrigtohill
County Cork, T45 DP77
Ireland
Name of the manufacturer of the biological active substance
BSP Pharmaceuticals S.p.A.
Via Appia km 65,561
04013 Latina Scalo (LT)
Italy
Name and address of the manufacturer(s) responsible for batch releaseGilead Sciences Ireland UC
IDA Business and Technology Park
Carrigtohill
Co. Cork, T45 DP77
Ireland
Max shelf life
3 years
Storage conditions
2°C – 8°C
List of excipients
2-(N-morpholino)ethane sulfonic acid (MES)
Polysorbate 80 (E433)
Trehalose dihydrate

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

we are recruiting